24 Mar 2017 European Medicines Agency’s CHMP Recommends Approval of Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma
24 Mar 2017 European Commission Approves AMGEVITA™ (Biosimilar Adalimumab) For The Treatment Of Certain Inflammatory Diseases
24 Mar 2017 Almirall and Sun Pharma Announce Regulatory Filing of Tildrakizumab in Europe
24 Mar 2017 FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
24 Mar 2017 FDA Grants Approval for BAVENCIO® (avelumab), the First Immunotherapy Approved for Metastatic Merkel Cell Carcinoma
24 Mar 2017 ImmunoGen has elected not to exercise its late stage co-development option for the US-Market with Biotest’s antibody-drug conjugate (BT-062)
23 Mar 2017 Alligator announces completion of first phase I study with CD40 agonistic immuno-oncology antibody ADC-1013
22 Mar 2017 Netris Pharma Starts Enrollment of First Clinical Study to Evaluate Drug Candidate Targeting Dependence Receptors
21 Mar 2017 Phase 1/2 Clinical Trial of Apexigen's APX005M in Combination with Pembrolizumab (Keytruda®) Opens for Metastatic Melanoma Patients
21 Mar 2017 EnGeneIC Doses First Patient in U.S. Phase 1 Clinical Study of Targeted EDV™ Nanocells in Recurrent Glioblastoma Multiforme
21 Mar 2017 Syntimmune Announces Breakthrough Results of FcRn Inhibition Published in PNAS
21 Mar 2017 Novartis' Cosentyx is first and only IL-17A inhibitor to potentially modify the course of psoriasis
20 Mar 2017 Lowering LDL Levels With Repatha® (Evolocumab) Did Not Adversely Affect Cognitive Function In Landmark Phase 3 Study
18 Mar 2017 Landmark Outcomes Study Shows That Repatha® (Evolocumab) Decreases LDL-C To Unprecedented Low Levels And Reduces Risk Of Cardiovascular Events With No New Safety Issues
17 Mar 2017 Nordic Nanovector Announces First Patient Dosed in Phase 1 Study of Betalutin® in Diffuse Large B-cell Lymphoma (DLBCL), an Aggressive Form of NHL
17 Mar 2017 Therapeutic antibodies account for two-thirds of total biologics sales in 2016
15 Mar 2017 FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Adult and Pediatric Patients with Classical Hodgkin Lymphoma (cHL) Refractory to Treatment, or Who Have Relapsed After Three or More Prior Lines of Therapy
14 Mar 2017 Repatha® (Evolocumab) Demonstrates Reduced Need For Apheresis In Patients With High LDL Cholesterol In Phase 3 Study
13 Mar 2017 ImmunoGen Presents Phase 1 Biopsy Expansion Cohort Data at the Society of Gynecologic Oncology Annual Meeting
08 Mar 2017 FDA Accepts sBLA Filing of Soliris(R) (Eculizumab) as a Potential Treatment for Patients with Refractory Generalized Myasthenia Gravis (gMG)
07 Mar 2017 Novartis' Cosentyx shows almost all psoriasis patients rapidly regain skin clearance following a treatment pause
07 Mar 2017 Sanofi and Regeneron Announce Presentation of Positive Data from Long-Term Pivotal Phase 3 CHRONOS Study of Dupixent® (dupilumab) in Moderate-to-Severe Atopic Dermatitis
07 Mar 2017 New Head-to-Head Data Shows Significantly Higher Response Rates for Lilly's Taltz® (ixekizumab) Compared to Stelara® (ustekinumab) in Patients with Moderate-to-Severe Plaque Psoriasis
07 Mar 2017 New data demonstrate Sandoz proposed biosimilar adalimumab has equivalent efficacy to reference medicine
07 Mar 2017 TG Therapeutics Announces Positive Topline Data from Phase 3 GENUINE Study of TG-1101 in Combination with Ibrutinib in Patients with High Risk Chronic Lymphocytic Leukemia (CLL)

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing